Supprelin LA is a hormone medication prescribed for children who have started puberty too early. This medicine works by decreasing the production of testosterone in boys and estrogen in girls. It comes in the form of an implant that is inserted just under the skin of the upper arm every 12 months. Side effects include bruising, soreness, and swelling.
What Is Supprelin LA?
Supprelin® LA (histrelin implant) is a prescription medication approved for use in children who have a condition called central precocious puberty. Children with this condition start puberty (when the body changes from a child's body into an adult body) too early.
Supprelin LA is a small, flexible implant that, once inserted under the skin, releases medicine into the body for a full year. It belongs to a group of medicines called gonadotropin-releasing hormone (GnRH) agonists, also known as luteinizing hormone-releasing hormone (LH-RH) agonists. Supprelin LA and other GnRH agonists are used to stop early puberty until the child is older.
Supprelin LA is manufactured by Endo Pharmaceuticals Solutions, Inc.
How Does Supprelin LA Work?
Supprelin LA is a synthetic (manufactured) form of gonadotropin-releasing hormone (GnRH), a naturally occurring hormone in the body. It controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland (a tiny gland located beneath the brain). LH and FSH stimulate the production of testosterone in the testes and estrogen in the ovaries.
Supprelin LA works by overstimulating the pituitary gland. When overstimulated, the pituitary does not make as much LH and FSH. As a result, the testes stop making testosterone and the ovaries stop making estrogen. This causes testosterone (in boys) and estrogen (in girls) levels to decrease, temporarily stopping puberty.
The Supprelin LA implant is specially formulated to slowly release medicine into the body over a 12-month period. This allows for once-a-year dosing.
Supprelin LA Web site. Available at: http://www.supprelinla.com/ Accessed July 1, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed July 1, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click